Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
Lancet Rheumatol
.
2022 Mar;4(3):e154-e155.
doi: 10.1016/S2665-9913(21)00418-5.
Epub 2021 Dec 23.
Authors
L Boekel
1
,
G J Wolbink
1
2
3
Affiliations
1
Department of Rheumatology, Reade, location Dr. Jan van Breemenstraat, Amsterdam Rheumatology and Immunology Center, Amsterdam 1056 AB, Netherlands.
2
Department of Immunopathology, Sanquin Research, Amsterdam, Netherlands.
3
Landsteiner Laboratory Academic Medical Center, Amsterdam, Netherlands.
PMID:
34977601
PMCID:
PMC8700274
DOI:
10.1016/S2665-9913(21)00418-5
No abstract available